BG-60366
- Generic Name
- BG-60366
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerLung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)EGFR Activating MutationEGFR Mutation-Related Tumors
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT06685718
- Locations
- 🇰🇷
Chungbuk National University Hospital, SeowonGu CheongjuSi, Chungcheongbukdo, Korea, Republic of
🇰🇷Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath